Anika Therapeutics (ANIK) Projected to Post Quarterly Earnings on Thursday

Anika Therapeutics (NASDAQ:ANIK) is anticipated to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Anika Therapeutics to post earnings of $0.02 per share and revenue of $28.8750 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Anika Therapeutics Stock Performance

Shares of Anika Therapeutics stock opened at $10.52 on Thursday. Anika Therapeutics has a 52-week low of $7.87 and a 52-week high of $18.19. The stock has a market capitalization of $151.70 million, a price-to-earnings ratio of -4.61 and a beta of 0.43. The company’s 50 day moving average price is $9.66 and its 200-day moving average price is $9.41.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Anika Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Barrington Research reiterated an “outperform” rating and set a $16.00 target price on shares of Anika Therapeutics in a report on Friday, January 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Anika Therapeutics in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Anika Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $18.50.

Institutional Trading of Anika Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new stake in Anika Therapeutics during the 3rd quarter valued at approximately $71,000. Occudo Quantitative Strategies LP purchased a new position in shares of Anika Therapeutics in the 3rd quarter valued at approximately $95,000. Ieq Capital LLC bought a new stake in shares of Anika Therapeutics during the fourth quarter valued at approximately $97,000. Mercer Global Advisors Inc. ADV purchased a new stake in Anika Therapeutics in the fourth quarter worth $122,000. Finally, Jain Global LLC purchased a new stake in Anika Therapeutics in the fourth quarter worth $137,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.